Spectral AI Taps Medical Device Veteran Bajko as CCO to Drive Burn Care System Launch
Event summary
- Darcy Bajko joins Spectral AI as Chief Commercial Officer on July 31, 2026.
- Bajko previously led commercialization at MediView XR and held roles at Integra LifeSciences and Smith+Nephew.
- Spectral AI aims to close first commercial sales of its FDA-cleared DeepView® System by year-end 2026.
- DeepView System combines multispectral imaging with AI for burn wound assessment.
The big picture
Spectral AI's appointment of Darcy Bajko as CCO signals a strategic shift toward aggressive commercialization following FDA clearance for its DeepView System. The move comes amid growing industry recognition of AI-driven diagnostics in wound care, positioning Spectral AI to compete with established medical device players like Integra LifeSciences and Smith+Nephew. Success will hinge on Bajko's ability to build a high-performing sales team and drive clinical adoption across key healthcare settings.
What we're watching
- Commercial Execution
- Whether Bajko can replicate her success at MediView XR in scaling Spectral AI's sales organization.
- Market Adoption
- The pace at which burn centers and emergency departments adopt the DeepView System post-FDA clearance.
- Revenue Trajectory
- How quickly Spectral AI can transition from product development to generating commercial revenue streams.